Autistic Disorder Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight

The prevalence of the autistic disorder has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of autistic disorder and the growing research and development activities to develop novel therapies to treat autistic disorder to drive the market. The companies developing the potential therapies in the last stage of development include MapLight Therapeutics, Jazz Pharmaceuticals, Yamo pharmaceuticals, and several others.


New York, USA, March 09, 2023 (GLOBE NEWSWIRE) -- Autistic Disorder Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight

The prevalence of the autistic disorder has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of autistic disorder and the growing research and development activities to develop novel therapies to treat autistic disorder to drive the market. The companies developing the potential therapies in the last stage of development include MapLight Therapeutics, Jazz Pharmaceuticals, Yamo pharmaceuticals, and several others.

DelveInsight’s 'Autistic Disorder Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline autistic disorder therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the autistic disorder pipeline domain.

Key Takeaways from the Autistic Disorder Pipeline Report

  • DelveInsight’s autistic disorder pipeline report depicts a robust space with 25+ active players working to develop 28+ pipeline therapies for autistic disorder treatment. 
  • Key autistic disorder companies such as Scioto Biosciences, ACADIA Pharmaceuticals Inc., Yamo Pharmaceuticals LLC, Stalicla SA, MapLight Therapeutics, Jazz Pharmaceuticals, Neurotech International, Axial Therapeutics, Inc., Hoffmann-La Roche, Impel Pharmaceuticals, PaxMedica, SciSparc Ltd., BrainStorm Cell Therapeutics, Enterin, Monument Therapeutics, IAMA Therapeutics, Confluence Pharmaceuticals, 4D Pharma PLC, and others are evaluating new autistic disorder drugs to improve the treatment landscape.
  • Promising autistic disorder pipeline therapies such as SB 121, Pimavanserin, FEN164, L1-79, ML-004, GWP42003-P, STP1, NTI164, AB-2004, RO7017773, INP105, PAX-101, SCI-210, Autologous MSC-NTF, ENT-01, MT 1988, IAMA-6, IAMA 097, MRx0006, and others are under different phases of autistic disorder clinical trials.
  • In February 2023, PaxMedica, Inc., for the treatment of disorders with intractable neurologic symptoms, announced that the Company has signed a funding agreement for net proceeds of $3.2 million with Lind Global Partners II, LP, an investment fund managed by The Lind Partners, a New York based institutional fund manager (together “Lind”). This funding will give the flexibility to progress on the work PaxMedica are doing for the development of the autism spectrum disorder (ASD) indication for PAX-101. PaxMedica appreciates the Lind Group’s support for work to find treatments for disorders with intractable neurologic symptoms such as ASD.
  • In January 2023, SciSparc Ltd.  announced it had signed an agreement with the Soroka University Medical Center, in Be'er-Sheva, Israel ("Soroka Medical Center") to conduct the Company’s clinical study for SCI-210 in patients suffering from autism spectrum disorder ("ASD").
  • In July 2022, Impel Pharmaceuticals  announced the first subject had been dosed in a Phase IIa proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic. INP105 is being developed as an acute treatment for agitation in persons with autism spectrum disorder (ASD) using Impel’s proprietary Precision Olfactory Delivery (POD®) technology which delivers drugs to the upper nasal space.
  • In May 2022, Scioto Biosciences, Inc. (Scioto) announced top-line results of its Phase Ib trial of lead asset SB-121, based on its novel microbiome delivery platform, Activated Bacterial Therapeutics (ABT), which is designed to deliver best-in-class, live therapeutic bacteria to the gut. This first-in-human study was a randomized, double-blind, placebo-controlled, 28-day daily-dose crossover study of the safety and tolerability of SB-121 (Lactobacillus reuteri with dextran microparticles and maltose) in patients ages 15 to 45 years, diagnosed with autism spectrum disorder (ASD).
  • In February 2022, Axial Therapeutics announced the publication in Nature Medicine of full results from its Phase Ib/IIa clinical trial of AB-2004. AB-2004 was shown to have strong safety and tolerability across all dose levels, and no drug-related serious adverse events were identified. AB-2004 reduced anxiety and irritability based on scores on the Aberrant Behavior Checklist - Irritability domain (ABC-I) and the Pediatric Anxiety Rating Scale (PARS). Individuals with high baseline irritability (scores ≥ 15), which represents the top quartile of severity, displayed a greater than 9-point decrease in ABC-I over 8 weeks.

Request a sample and discover the recent advances in autistic disorder treatment drugs @ Autistic Disorder Pipeline Report

The autistic disorder pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage autistic disorder drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the autistic disorder clinical trial landscape.

Autistic Disorder Overview

Autism spectrum disorder (ASD) is a neurodevelopmental disorder marked by social communication deficits, restricted interests, and repetitive behaviors. ASD has no clear pathology, but different populations have been proposed for different subtypes of ASD. Autism spectrum disorder symptoms are typically identified by the age of two (specifically for CDD, one-third of children experience regression of skills simultaneously). Children with childhood disintegrative disorder have the worst outcomes among ASD patients.

Childhood disintegrative disorder is rarely associated with an underlying neurological or medical cause in children. Comprehensive medical and neurological examinations are performed, as well as tests to rule out reversible causes of the condition. Treatment for childhood disintegrative disorder includes a combination of behavior therapy, environmental therapy, and medication. Because no drug can directly cure this disease, medications are used to treat the symptoms as they arise.


Find out more about autistic disorder treatment drugs @ Drugs for Autistic Disorder Treatment

A snapshot of the Autistic Disorder Pipeline Drugs mentioned in the report:

DrugsCompanyPhase MoARoA
NTI164Neurotech InternationalPhase II/IIINANA
GWP42003-PJazz PharmaceuticalsPhase IICannabinoid receptor CB2 inverse agonistsOral
ML-004MapLight TherapeuticsPhase IISerotonin receptor agonistsOral
FEN164Neurotech InternationalPhase I/IINAOral
L1-79Yamo pharmaceuticalsPhase IITyrosine hydroxylase inhibitorsOral
SB 121Scioto BiosciencesPhase IBacteria replacements; Microbiome modulatorsOral

Learn more about the emerging autistic disorder pipeline therapies @ Autistic Disorder Clinical Trials

Autistic Disorder Therapeutics Assessment

The autistic disorder pipeline report proffers an integral view of the autistic disorder emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Autistic Disorder Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Intravenous, Oral, Parenteral, Subcutaneous, Topical
  • Therapeutics Assessment By Molecule Type: Gene therapy, Peptides, Polymer, Small molecule
  • Therapeutics Assessment By Mechanism of Action: Enzyme modulators, Enzyme replacements, Tyrosine hydroxylase inhibitors, Bacteria replacements, Microbiome modulators
  • Key Autistic Disorder Companies: Scioto Biosciences, ACADIA Pharmaceuticals Inc., Yamo Pharmaceuticals LLC, Stalicla SA, MapLight Therapeutics, Jazz Pharmaceuticals, Neurotech International, Axial Therapeutics, Inc., Hoffmann-La Roche, Impel Pharmaceuticals, PaxMedica, SciSparc Ltd., BrainStorm Cell Therapeutics, Enterin, Monument Therapeutics, IAMA Therapeutics, Confluence Pharmaceuticals, 4D Pharma PLC and others
  • Key Autistic Disorder Pipeline Therapies: SB 121, Pimavanserin, FEN164, L1-79, ML-004, GWP42003-P, STP1, NTI164, AB-2004, RO7017773, INP105, PAX-101, SCI-210, Autologous MSC-NTF, ENT-01, MT 1988, IAMA-6, IAMA 097,  MRx0006 and others

Dive deep into rich insights for new drugs for autistic disorder treatment, visit @ Autistic Disorder Drugs

Table of Contents

1.Autistic Disorder Pipeline Report Introduction
2.Autistic Disorder Pipeline Report Executive Summary
3.Autistic Disorder Pipeline: Overview
4.Analytical Perspective In-depth Commercial Assessment
5.Autistic Disorder Clinical Trial Therapeutics
6.Autistic Disorder Pipeline: Late Stage Products (Pre-registration)
7.Autistic Disorder Pipeline: Late Stage Products (Phase III)
8.Autistic Disorder Pipeline: Mid Stage Products (Phase II)
8.1.ML-004: MapLight Therapeutics
9.Autistic Disorder Pipeline: Early Stage Products (Phase I)
9.1.SB 121: Scioto Biosciences
10.Autistic Disorder Pipeline Therapeutics Assessment
11.Inactive Products in the Autistic Disorder Pipeline
12.Company-University Collaborations (Licensing/Partnering) Analysis
13.Key Companies
14.Key Products in the Autistic Disorder Pipeline
15.Unmet Needs
16.Market Drivers and Barriers
17.Future Perspectives and Conclusion
18.Analyst Views
19.Appendix

For further information on the autistic disorder pipeline therapeutics, reach out @ Autistic Disorder Treatment Drugs

Related Reports

Autism Spectrum Disorder Epidemiology

Autism Spectrum Disorder Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted autism spectrum disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Autism Spectrum Disorder Market

Autism Spectrum Disorder Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key autism spectrum disorder companies, including Stalicla SA, MapLight Therapeutics, Jazz Pharmaceuticals, among others.

Autism Pipeline

Autism Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Autism companies,  including Scioto Biosciences, ACADIA Pharmaceuticals Inc., Yamo Pharmaceuticals LLC, Stalicla SA, among others.

Autism Epidemiology Forecast

Autism Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted autism epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Epilepsy Market

Epilepsy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies, including Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, among others.

Epilepsy Pipeline

Epilepsy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key epilepsy companies, including Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 

 

Contact Data